Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
Public ClinicalTrials.gov record NCT03945292. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).
Study identification
- NCT ID
- NCT03945292
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 7, 2019 (Actual)
- Primary completion
- Nov 8, 2021 (Actual)
- Completion
- Sep 18, 2023 (Actual)
- Last update posted
- Nov 4, 2025
2019 – 2023
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site 5 | Birmingham | Alabama | 35233 | — |
| Research Site 9 | Phoenix | Arizona | 85054 | — |
| Research Site 14 | La Jolla | California | 92037 | — |
| Research Site 17 | Los Angeles | California | 90095 | — |
| Research Site 11 | Sacramento | California | 95817 | — |
| Research Site 15 | San Francisco | California | 94158 | — |
| Research Site 13 | Stanford | California | 94305 | — |
| Research Site 2 | Gainesville | Florida | 32610 | — |
| Research Site 7 | Indianapolis | Indiana | 46202 | — |
| Research Site 3 | Iowa City | Iowa | 52242 | — |
| Research Site 10 | St Louis | Missouri | 63104 | — |
| Research Site 12 | New York | New York | 10032 | — |
| Research Site 1 | Charleston | South Carolina | 29425 | — |
| Research Site 4 | Nashville | Tennessee | 37232 | — |
| Research Site 19 | Houston | Texas | 77030 | — |
| Research Site 16 | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03945292, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2025 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03945292 live on ClinicalTrials.gov.